This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n24http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/pubchem-compound/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n26http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n23http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/iuphar/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/guide-to-pharmacology/
n13http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n4http://www.drugs.com/mtm/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/chemspider/
n27http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/chebi/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n25http://linked.opendata.cz/ontology/mesh/
n5http://linked.opendata.cz/ontology/drugbank/
n11http://www.rxlist.com/cgi/generic2/
n6http://linked.opendata.cz/resource/drugbank/property/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/pharmgkb/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/wikipedia/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/pdb/
n19http://linked.opendata.cz/ontology/sukl/drug/
n20http://linked.opendata.cz/resource/atc/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01244/identifier/kegg-compound/

Statements

Subject Item
n2:DB01244
rdf:type
n5:Drug
n5:description
A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. [PubChem] It is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes).
n5:group
withdrawn approved
n5:halfLife
24-50 hours
n5:indication
For the treatment of hypertension, and chronic stable angina (classic effort-associated angina).
owl:sameAs
n13:DB01244 n27:DB01244
dcterms:title
Bepridil
adms:identifier
n8:PA164754755 n9:Bepridil n14:2261 n15:DB01244 n16:3061 n17:C06847 n18:BEP n21:2337 n22:2337 n23:46506353 n24:2351
n5:mechanismOfAction
Bepridil has inhibitory effects on both the slow calcium (L-type) and fast sodium inward currents in myocardial and vascular smooth muscle, interferes with calcium binding to calmodulin, and blocks both voltage and receptor operated calcium channels. Bepridil inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle. This has been demonstrated in isolated myocardial and vascular smooth muscle preparations in which both the slope of the calcium dose response curve and the maximum calcium-induced inotropic response were significantly reduced by bepridil. In cardiac myocytes <i>in vitro</i>, bepridil was shown to be tightly bound to actin. Bepridil regularly reduces heart rate and arterial pressure at rest and at a given level of exercise by dilating peripheral arterioles and reducing total peripheral resistance (afterload) against which the heart works.
n5:synonym
Bepadin Bepridil
n5:toxicity
There has been one experience with overdosage in which a patient inadvertently took a single dose of 1600 mg of bepridil. The patient was observed for 72 hours in intensive care, but no significant adverse experiences were noted.
n5:foodInteraction
Alcohol may further decrease blood pressure and increase dizziness and drowsiness Take with food to reduce nausea.
n5:proteinBinding
99%
n5:synthesisReference
Mauvernay, R.Y., Busch, N., Moleyre, J., Monteil, A. and Simond, J.; U.S. Patent 3,962,238; June 8,1976; assigned to Centre Europeen de Recherches Mauvernay "CERM".
n25:hasConcept
n26:M0024153
foaf:page
n4:bepridil.html n11:bepridil.htm
n5:IUPAC-Name
n6:271B5E46-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5E4C-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5E4B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5E48-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5E49-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5E4A-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5E44-363D-11E5-9242-09173F13E4C5 n6:271B5E5B-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5E42-363D-11E5-9242-09173F13E4C5 n6:271B5E45-363D-11E5-9242-09173F13E4C5 n6:271B5E5D-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5E43-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n20:C08EA02
n5:H-Bond-Acceptor-Count
n6:271B5E52-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5E53-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5E4D-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5E4E-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5E50-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5E4F-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5E51-363D-11E5-9242-09173F13E4C5
n5:absorption
Rapidly and completely absorbed after oral administration.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
64706-54-3
n5:category
n5:Bioavailability
n6:271B5E57-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5E59-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5E5A-363D-11E5-9242-09173F13E4C5
n5:Melting-Point
n6:271B5E5C-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5E56-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5E55-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5E58-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5E47-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5E54-363D-11E5-9242-09173F13E4C5